WallStreetZenWallStreetZen

NASDAQ: CALT
Calliditas Therapeutics Ab Stock

Open Broker Account
$18.56+0.35 (+1.92%)
Updated Dec 9, 2022
CALT Price
$18.56
Fair Value Price
$46.21
Market Cap
$548.51M
52 Week Low
$10.82
52 Week High
$27.50
P/E
-8.5x
P/B
8.06x
P/S
14.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.37M
Earnings
-$59.62M
Gross Margin
99.1%
Operating Margin
-183.19%
Profit Margin
-177.2%
Debt to Equity
1.02
Operating Cash Flow
-$60M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CALT Overview

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CALT ($18.56) is undervalued by 59.84% relative to our estimate of its Fair Value price of $46.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CALT ($18.56) is significantly undervalued by 59.84% relative to our estimate of its Fair Value price of $46.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CALT due diligence checks available for Premium users.

Be the first to know about important CALT news, forecast changes, insider trades & much more!

CALT News

Valuation

CALT fair value

Fair Value of CALT stock based on Discounted Cash Flow (DCF)
Price
$18.56
Fair Value
$46.21
Undervalued by
59.84%
CALT ($18.56) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CALT ($18.56) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CALT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.5x
Industry
19.37x
Market
21.21x

CALT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.06x
Industry
1.75x
CALT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CALT's financial health

Profit margin

Revenue
$6.3M
Net Income
-$18.9M
Profit Margin
-300.4%
CALT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CALT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$143.0M
Liabilities
$72.3M
Debt to equity
1.02
CALT's short-term assets ($89.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CALT's short-term assets ($89.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$22.1M
Investing
-$13.6k
Financing
$23.1M
CALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CALT vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
CALT$548.51M+1.92%-8.50x8.06x
AVDL$524.50M-1.28%-3.81x-42.16x
PAHC$513.99M+0.16%11.03x1.96x
SNDL$592.08M-4.21%-3.06x0.56x
EBS$604.15M-2.81%14.77x0.42x

Calliditas Therapeutics Ab Stock FAQ

What is Calliditas Therapeutics Ab's quote symbol?

NASDAQ: CALT) Calliditas Therapeutics Ab trades on the NASDAQ under the ticker symbol CALT. Calliditas Therapeutics Ab stock quotes can also be displayed as NASDAQ: CALT.

If you're new to stock investing, here's how to buy Calliditas Therapeutics Ab stock.

What is the 52 week high and low for Calliditas Therapeutics Ab (NASDAQ: CALT)?

(NASDAQ: CALT) Calliditas Therapeutics Ab's 52-week high was $27.50, and its 52-week low was $10.82. It is currently -32.51% from its 52-week high and 71.53% from its 52-week low.

How much is Calliditas Therapeutics Ab stock worth today?

(NASDAQ: CALT) Calliditas Therapeutics Ab currently has 59,106,188 outstanding shares. With Calliditas Therapeutics Ab stock trading at $18.56 per share, the total value of Calliditas Therapeutics Ab stock (market capitalization) is $548.51M.

Calliditas Therapeutics Ab stock was originally listed at a price of $19.60 in Jun 5, 2020. If you had invested in Calliditas Therapeutics Ab stock at $19.60, your return over the last 2 years would have been -5.31%, for an annualized return of -2.69% (not including any dividends or dividend reinvestments).

How much is Calliditas Therapeutics Ab's stock price per share?

(NASDAQ: CALT) Calliditas Therapeutics Ab stock price per share is $18.56 today (as of Dec 9, 2022).

What is Calliditas Therapeutics Ab's Market Cap?

(NASDAQ: CALT) Calliditas Therapeutics Ab's market cap is $548.51M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Calliditas Therapeutics Ab's market cap is calculated by multiplying CALT's current stock price of $18.56 by CALT's total outstanding shares of 59,106,188.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.